| COVID-19 |
1 |
1 |
| Myocarditis |
0 |
0.99 |
| Cardiomyopathy |
0 |
0.81 |
| Cardiogenic Shock |
0 |
0.19 |
| Cardiopulmonary Resuscitation |
0 |
0.14 |
| Multiple Organ Dysfunction Syndrome (MODS) |
0 |
0.14 |
| Antiviral Agents |
0 |
0.13 |
| Organ Failure |
0 |
0.13 |
| Pericardial Effusion |
0 |
0.13 |
| Refractory |
0 |
0.13 |
| Resuscitation |
0 |
0.13 |
| Shock |
0 |
0.13 |
| Ejection Fraction |
0 |
0.12 |
| Extracorporeal Membrane Oxygenation (ECMO) |
0 |
0.12 |
| Intensive Care Unit |
0 |
0.12 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.12 |
| Biologic Therapy |
0 |
0.11 |
| Cardiovascular Imaging |
0 |
0.11 |
| Cancer |
0 |
0.07 |
| Cannulation |
0 |
0.07 |
| Child |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Corticosteroids |
0 |
0.07 |
| Cytokines |
0 |
0.07 |
| Hemodynamics |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Immunization |
0 |
0.07 |
| Immunoglobulin A (IgA) |
0 |
0.07 |
| Injury |
0 |
0.07 |
| Interleukin |
0 |
0.07 |
| Intravenous |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Texas |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Heart Failure (HF) |
0 |
0.06 |
| Wound Management |
0 |
0.06 |